Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V) Therapy

Authors

Kyle C. Roche, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.
Peter A. DeRosa, Department of Pathology, The University of Maryland Medical Center, Baltimore, MD 21201, USA.
Min-Ling Liu, Department of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.
Victor E. Nava, Department of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.
Anita Aggarwal, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC 20037, USA.

Document Type

Journal Article

Publication Date

6-6-2022

Journal

Current oncology (Toronto, Ont.)

Volume

29

Issue

6

DOI

10.3390/curroncol29060328

Keywords

Bortezomib (Velcade); Venetoclax; chemotherapy refractory; progression without transformation; relapsed/refractory (R/R); splenic marginal zone lymphoma (SMZL)

Abstract

Standard treatment regimens for the management of patients with refractory splenic marginal zone lymphoma (SMZL) are currently unavailable. Here, we report a case of SMZL, which, after failing multiple therapeutics, demonstrated an impressive clinical response to combined Venetoclax and Velcade (V), a treatment combination currently being investigated in the setting of refractory multiple myeloma. We also report a unique histopathology and mutational profile that may have important implications for the characterization and prognosis of SMZL.

APA Citation

Roche, Kyle C.; DeRosa, Peter A.; Liu, Min-Ling; Nava, Victor E.; and Aggarwal, Anita, "Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V) Therapy" (2022). GW Authored Works. Paper 1153.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/1153

Department

Pathology